Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
11.18
-0.04 (-0.36%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Silence Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Silence Therapeutics stock has a consensus rating of "Buy" and an average price target of $33. The average 1-year stock price forecast is 195.17% higher than the current stock price, while the lowest is $10 (-10.55%) and the highest is $75 (+570.84%).
Price Target: $33 (+195.17%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Silence Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $75 | Buy | Maintains | $75 | +570.84% | Sep 21, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 10, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $25 → $32 | Buy | Reiterates | $25 → $32 | +186.23% | Aug 11, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $4 | Sell | Maintains | $4 | -64.22% | Jul 27, 2026 |
Financial Forecast
Revenue This Year
430.86K
from 559.00K
Decreased by -22.92%
Revenue Next Year
1.00M
from 430.86K
Increased by 132.77%
EPS This Year
-0.36
EPS Next Year
-0.38
from -0.36
EPS and Forward PE are based on non-GAAP adjusted numbers.